Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 417-431

  Stein, Evan A ^a   Raal, Frederick ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

LDL cholesterol; LDL receptors; Monoclonal antibodies

Indexed keywords

APOLIPOPROTEIN B; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIPID BLOOD LEVEL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MOLECULAR TARGETED THERAPY; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84899112104     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-022613-090402     Document Type: Article

References (35)

1. Abifadel M, Varret M, Rabés JP, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34:154-56 (Pubitemid 36666925)
2. Seidah NG, Benjannet S, Wickham L, et al. 2003. The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 100(3):928-33 (Pubitemid 36183932)
3. MaxwellKN, Breslow JL. 2004. Adenoviral-mediated expression of PCSK9 inmice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA 101:7100-5 (Pubitemid 38596449)
4. Maxwell KN, Fisher EA, Breslow JL. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA 102(6):2069-74 (Pubitemid 40262013)
5. Rashid S, Curtis DE, Garuti R, et al. 2005. Horton decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 102:5374-79 (Pubitemid 40530265)
6. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264-72
7. Leren TP. 2004. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin. Genet. 65(5):419-22 (Pubitemid 38659713)
8. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79(3):514-23 (Pubitemid 44384260)
9. Hooper AJ, Marais AD, Tanyanyiwa DM, et al. 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193(2):445-48 (Pubitemid 47058112)
10. Lagace TA, Curtis DE, Garuti R, et al. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116:2995-3005 (Pubitemid 44684484)
11. Chan JC, Piper DE, Cao Q, et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA 106:9820- 25
12. Stein EA, Mellis S, Yancopoulos GD, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366:1108-18
13. Dias CS, Shaywitz AJ, Wasserman SM, et al. 2012. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60:1888-98
14. McKenney JM, Koren MJ, Kereiakes DJ, et al. 2012. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59:2344- 53
15. Koren MJ, Scott R, Kim JB, et al. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380:1995-2006
16. Giugliano RP, Desai NR, Huang F, LAPLACE-TIMI 57 Investigators. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380:2007-17
17. Roth EM, McKenney JM, Hanotin C, et al. 2012. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367:1891-900
18. Stein EA, Gipe D, Bergeron J, et al. 2012. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dosewith orwithout ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380:29-36
19. Raal F, Scott R, Somaratne R, et al. 2012. Low-density lipoprotein cholesterol-lowering effects of AMG 145, amonoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder(RUTHERFORD)randomized trial. Circulation 126:2408-17
20. Sullivan D, Olsson AG, Scott R, et al. 2012. Effect ofAMG145, amonoclonal antibody to PCSK9, onLDL cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308(23):2497-506
21. Stein EA, Swergold GD. 2013. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr. Atheroscler. Rep. 15:310
22. Lambert G, Sjouke B, Choque B, et al. 2012. The PCSK9 decade. J. Lipid Res. 53:2515-24 Sanofi and Regeneron phase 3 clinical program with alirocumab. http://www.clinicaltrials.gov/ct2/resultsterm=alirocumab&Search=Search. Accessed Sep. 10, 2013
23. Amgen 145 phase 3 trials. http://www.clinicaltrials.gov/ct2/resultsterm= AMG+145&Search= Search. Accessed Sep. 10, 2013
24. A Study of LY3015014 in Participants With High Cholesterol. http://www.clinicaltrials.gov/ct2/show/NCT01890967term=PCSK9&rank=29. Accessed Sep. 10, 2013
25. Anti-PCSK9 (MPSK3169A, RG7652) is a monoclonal antibody directed against PCSK9 (proprotein convertase subtilisin/kexin type 9). http://www.gene.com/ medical-professionals/pipeline and http://www.clinicaltrials.gov/ct2/show/ NCT01609140term=MPSK3169A&rank=1. Accessed Sep. 10, 2013
26. Gumbiner B, Joh T, Udata C, et al. 2012. Effects of 12 weeks of treatment with RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects on high- and maximal-dose statins. Circulation 126(23):2782 (Abstr.)
27. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes). http://clinicaltrials.gov/ct2/show/NCT01663402. Accessed July 7, 2013
28. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/ NCT01764633term=AMG+145&rank=18. Accessed July 7, 2013
29. Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-89
30. Baigent C, Blackwell L, Emberson J, et al. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 376:1670-81
31. Ridker PM, Danielson E, Fonseca FA, et al. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359:2195-207
32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-97
33. Reiner Z, Catapano AL, De Backer G, et al. 2011. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32:1769-818
34. Stein E, Stender S, Mata P, et al. 2004. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Ezetimibe Study Group. Am. Heart J. 148:447-55
35. Bruckert E, Hayem G, Dejager S, et al. 2005. Mild to moderate muscular symptoms with high dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc. Drugs Ther. 19(6):403-14 (Pubitemid 43228152)